Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Combined With Immunochemotherapy in Newly Diagnosed CLL
NCT04980859Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Phase 3, open-label, single-arm trial of zanubrutinib in chronic lymphocytic leukemia (CLL), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Minimal Residual Disease conversion rate at 30 days. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04980859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980859.